

AMERICAN VIETNAMESE BIOTECH INC
INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

has been reviewed by

NHAN TAM VIET AUDITING COMPANY LIMITED

INDEX

Content	Page
Report of the Board of Directors	2-4
Report the results of the review work	5-6
The interim financial statements have been reviewed	7-40
Balance sheet as of June 30, 2024	7-10
Report on interim business results for the first 6 months of the fiscal year ending December 31, 20224	11
Interim cash flow report for the first 6 months of the fiscal year ending December 31, 2024	12-13
Notes to the interim financial statements for the first 6 months of the fiscal year ending December 31, 2024	14-40

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors of American VietNameese Biotech INC (hereinafter referred to as the "Company") presents its report together with the audited interim financial statements for the first 6 months of the fiscal year ending December 31, 2024.

Company Overview

American VietNameese Biotech INC was established under Business Registration Certificate No.3800237998 First issued by the Department of Planning and Investment of Ho Chi Minh City on August 26, 2002. During its operation, the Company has changed its business registration certificate 23 times. The 23rd change in the business registration certificate of a joint stock company was issued on August 5, 2024.

Charter capital according to the 23rd Business Registration Certificate: VND 1,311,056,500,000
Actual contributed capital as of June 30, 2024: VND 1,311,056,500,000

Headquarters:

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

Phone: 0651.3.889034

Fax: 0651.3.889032

Tax code: 3 8 0 0 2 3 7 9 9 8

Financial situation and business operations

The Company's interim financial position as of June 30, 2024, interim results of operations and interim cash flows for the first 6 months of the fiscal year ended December 31, 2024 are presented in the Financial Statements attached to this report (from page 07 to page 40).

Significant events occurring during and subsequent to the end of the accounting period

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model
- built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. Currently, the Company is carrying out the necessary procedures to put the chain of clinic companies in all 63 provinces and cities across the country into operation, with the expectation of providing early, reliable diagnostic tests at the most cost-effective cost at the chain of testing centers. This issue was also approved at the 2024 Annual General Meeting of Shareholders.
- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Maternity and Pediatrics Hospital,

AMERICAN VIETNAMESE BIOTECH INC

BOARD OF DIRECTORS' REPORT (next)

the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 8,000,000,000 to the company.

- Resolution of the Board of Directors No. 2502.01/2025/NQ-HĐQT dated February 25, 2025 on divestment of investment capital at Vietnam National Software Production Joint Stock Company.

In addition to the above events, the Company's Board of Directors confirms that no other events have occurred up to the date of this report that have not been considered for adjustment of figures or disclosed in the Financial Statements.

Board of Directors and Management

Members of the Board of Directors, Board of Supervisors and Board of Management of the Company during the period and up to the date of this report include:

Board of Directors

<u>Full name</u>	<u>Position</u>
Mr. Nakatani Yoshitaka	Chairman
Mrs. Dang Nhi Nuong	Member
Mr. Le Khanh Nguyen	Member

Board of Control

<u>Full name</u>	<u>Position</u>
Mrs. Le Thi Huong	Head of The Control Board
Ms. Nguyen Huong Giang	Member
Ms. Vu Thu Thuy	Member

Board of Directors

<u>Full name</u>	<u>Position</u>
Mrs. Dang Nhi Nuong	Director

Chief Accountant

<u>Full name</u>
Ms. Le Thi Viet Ha

Auditor

Nhan Tam Viet Auditing Company Limited has audited the Interim Financial Statements for the first 6 months of the fiscal year ending December 31, 2024.

Confirmation from the Board of Directors

The Company's Board of Directors is responsible for preparing the Interim Financial Statements which give a true and fair view of the interim financial position, the interim results of operations and the interim cash flows of the Company during the period. In preparing the Interim Financial Statements, the Company's Board of Directors undertakes to comply with the following requirements:

- Establish and maintain internal controls that the Company's management determines are necessary to enable the preparation and presentation of interim financial statements that are free from material misstatement, whether due to fraud or error;
- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether the applicable accounting standards have been followed, and whether there are any material departures that need to be disclosed and explained in the interim financial statements;

AMERICAN VIETNAMESE BIOTECH INC

BOARD OF DIRECTORS' REPORT (next)

- Prepare and present interim financial statements in compliance with Vietnamese Accounting Standards, Enterprise Accounting Regime and legal regulations related to the preparation and presentation of interim financial statements;
- Prepare the interim financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Directors is responsible for ensuring that proper accounting records are kept which disclose with reasonable accuracy at any time the financial position of the Company and that the interim financial statements comply with the applicable State regulations. At the same time, it is responsible for safeguarding the assets of the Company and taking reasonable steps to prevent and detect fraud and other irregularities.

The Company's Board of Directors is committed that the Interim Financial Statements have fairly and fairly reflected the financial position of the Company as at June 30, 2024, the results of its operations and its cash flows for the first 6 months of the fiscal year ended December 31, 2024, in accordance with Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and in compliance with legal regulations related to the preparation and presentation of Interim Financial Statements.

Other commitments

Due to some objective reasons, the Company has not fulfilled its obligation to publish the Financial Statements audited by the Auditing Company within the prescribed time limit, so the Company's shares have been suspended from trading according to Decision No. 153/QĐ-SGDHN dated March 17, 2025 of the Hanoi Stock Exchange. The Company commits to fulfill its obligations immediately after issuing this Report together with the audited interim financial statements.

In addition to the above issue, the Board of Directors commits that the Company complies with Decree 155/2020/ND-CP dated December 31, 2020 guiding corporate governance applicable to public companies and the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the stock market.

Ho Chi Minh, 23 May, 2025

Director



Dang Nhi Nuong

Number : 2904.01.01/2025/BCTC-NTV2

REPORT ON REVIEW RESULTS
About Interim Financial Report
First 6 months of the fiscal year ending December 31, 2024

Dear : **Shareholders, Board of Directors, Management**
American VietNameese Biotech INC

We have reviewed the accompanying interim financial statements of American VietNameese Biotech INC, prepared on 23 May 2025 from page 07 to page 40, including the interim balance sheet as at 30 June 2024, the interim income statement, the interim cash flow statement for the first 6 months of the financial year ended 31 December 2024 and the notes to the interim financial statements.

Responsibilities of the Board of Directors

Board of Directors American VietNameese Biotech INC be responsible for the preparation and fair presentation of the interim financial statements in accordance with Vietnamese accounting standards, accounting regimes and legal regulations related to the preparation and presentation of interim financial statements and be responsible for the internal control that the Board of Directors determines is necessary to ensure the preparation and presentation of interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities

Our responsibility is to express a conclusion on the interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements No. 2410 - Review of interim financial information performed by the independent auditor of the entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis of audit conclusion except

- The Company is investing in Famicare Phap Van Joint Stock Company, the amount of VND 10,500,000,000, accounting for 35% of charter capital. Up to this point, Famicare Phap Van Joint Stock Company has not formed significant assets for production and business activities. Through the applied auditing procedures, we do not have sufficient basis to assess the reasonableness of the above investment as well as their impact on the interim financial statements for the first 6 months of the fiscal year ending December 31, 2024.

- The Company has invested and installed machinery, equipment, and RIS-PACS medical image storage and transmission software systems under lease contracts and cooperation agreements with hospitals and medical centers with an investment cost of VND 67,541,800,532 as of June 30, 2024 (of which the value handed over to the hospital for use is VND 40,953,427,745 and the value not yet handed over to the hospital is VND 26,588,372,787). Some hospitals have generated revenue, but due to the lack of specific and unified instructions on payment for imaging diagnostic technical services based on the PACS system, the Company still does not have enough reliable basis to fully determine

REPORT ON REVIEW RESULTS (CONTINUED)

the economic benefits gained from the above lease and cooperation. However, the Company has recorded depreciation expenses for the transferred assets in the business results of the years, the accumulated depreciation value as of June 30, 2024 is VND 18,573,725,968 (of which the accumulated value up to December 31, 2023 is VND 16,526,054,590, the depreciation for the first 6 months of 2024 is VND 2,047,671,378). By applying audit procedures, we have not determined their impact on the interim financial statements for the first 6 months of the fiscal year ending December 31, 2024.

Auditor's Conclusion

Based on our review, except for the effects of the matters described in the "Basis for Qualified Audit Opinion" paragraph, we have not come across anything that causes us to believe that the accompanying interim financial statements do not present fairly, in all material respects, the interim financial position of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company as at 30 June 2024, and the interim results of operations and interim cash flows of the entity for the first 6 months of the fiscal year ended 31 December 2024, in accordance with Vietnamese accounting standards, accounting regimes and legal regulations related to the preparation and presentation of interim financial statements.

Emphasis of Matters

As of June 30, 2024, the Company's loan at BVBank is VND 29,625,095,827 and is overdue. As of the issuance date of this report, the above loan is overdue. The extension request period stated in Official Letter No. 05/2024/CV-AMV of the Company was October 2024, and it was approved by BVBank in Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of now, the Company has not yet fully repaid the aforementioned principal amount and is continuing to work with the Bank to request an extension. (note V.17).

Other matters

The interim financial statements for the first 6 months of the fiscal year ending December 31, 2023 and the financial statements for the fiscal year ending December 31, 2023 of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company have been reviewed and audited by another auditing company. The independent audit report No. 201/BCKT-TC issued on March 29, 2024 expressed an unqualified opinion because the auditor could not estimate the net realizable value of the inventory of various types of software presented at original price at December 31, 2023: VND 140,080,690,416. Up to now, the entire value of the above-mentioned types of software has been sold, and all debts have been paid up to the time of preparing the report, so our audit opinion is no longer affected by this issue.

In addition, the 2023 Audit Report highlights the following items:

- + The company invested in and installed the RIS-PACS medical image transmission software system at hospitals and medical centers under cooperation contracts but has not recorded revenue from this activity. This issue has been stated in our exception conclusion.
- + The loan at BVBank as at December 31, 2023 is VND 31,623,165,292 and is overdue for payment. We continue to emphasize this issue in the Interim Audit Report for the first 6 months of the fiscal year ending December 31, 2024.

Ha Noi, 23 May, 2025

NHAN TAM VIET AUDITING COMPANY LIMITED

Deputy General Director



Nguyen Van Tan

Auditor's Certificate No. : 5348-2025-124-1

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

BALANCE SHEET

As of June 30, 2024

Unit: VND

ASSET	Cod e	Explanat ion	Ending Balance	Beginning Balance
A - SHORT-TERM ASSETS	100		293,833,721,914	320,752,651,952
I. Cash and cash equivalents	110	V.1	1,034,858,713	6,404,911,296
1. Cash	111		1,034,858,713	6,404,911,296
2. Cash equivalents	112		-	-
II. Short-term financial investment	120		-	-
1. Trading securities	121		-	-
2. Provision for impairment of trading securities	122		-	-
3. Held to maturity investment	123		-	-
III. Short-term receivables	130		151,049,007,841	153,124,423,200
1. Short-term trade receivables	131	V.2	49,969,509,721	39,531,334,576
2. Short-term vendor advance	132	V.3	95,646,903,965	113,153,578,000
3. Short-term internal receivables	133		-	-
4. Receivable according to construction contract progr	134		-	-
5. Short-term loan receivable	135	V.4	5,000,000,000	-
6. Other short-term receivables	136	V.5	679,209,284	514,885,909
7. Provision for doubtful short-term receivables	137	V.6	(246,615,129)	(75,375,285)
8. Assets missing pending resolution	139		-	-
IV. Inventory	140		141,582,441,474	160,972,611,648
1. Inventory	141	V.7	141,582,441,474	160,972,611,648
2. Provision for inventory write-down	149		-	-
V. Other short-term assets	150		167,413,886	250,705,808
1. Short-term prepaid expenses	151	V.8a	9,340,912	29,931,820
2. Deductible value added tax	152		158,072,974	220,773,988
3. Taxes and other amounts receivable from the State	153		-	-
4. Government bond repurchase transaction	154		-	-
5. Other short-term assets	155		-	-

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

Interim Balance Sheet (Cont.)

ASSET	Cod e	Explanat ion	Ending Balance	Beginning Balance
B - LONG-TERM ASSETS	200		1,374,298,426,510	1,364,943,625,545
I. Long-term receivables	210		-	-
1. Long-term receivables from customers	211		-	-
2. Long-term prepayment to seller	212		-	-
3. Working capital in affiliated units	213		-	-
4. Long-term internal receivables	214		-	-
5. Long-term loan receivable	215		-	-
6. Other long-term receivables	216		-	-
7. Provision for doubtful long-term receivables	219		-	-
II. Fixed assets	220		50,749,893,152	62,694,603,970
1. Tangible fixed assets	221	V.9	28,370,191,375	38,267,230,815
<i>Original price</i>	222		56,918,202,914	64,268,202,914
<i>Accumulated depreciation</i>	223		(28,548,011,539)	(26,000,972,099)
2. Financial lease fixed assets	224		-	-
<i>Original price</i>	225		-	-
<i>Accumulated depreciation</i>	226		-	-
3. Intangible fixed assets	227	V.10	22,379,701,777	24,427,373,155
<i>Original price</i>	228		40,953,427,745	40,953,427,745
<i>Accumulated depreciation</i>	229		(18,573,725,968)	(16,526,054,590)
III. Investment real estate	230		-	-
Original price	231		-	-
Accumulated depreciation	232		-	-
IV. Long-term unfinished assets	240		26,588,372,787	26,588,372,787
1. Long-term unfinished production and business costs	241		-	-
2. Cost of unfinished basic construction	242	V.11	26,588,372,787	26,588,372,787
V. Long-term financial investment	250	V.12	1,296,937,901,193	1,275,629,485,662
1. Investment in subsidiaries	251		1,289,040,000,000	1,289,040,000,000
2. Investment in joint ventures and associates	252		31,500,000,000	-
3. Investing in other entities	253		3,763,500,000	-
4. Long-term financial investment reserve	254		(27,365,598,807)	(13,410,514,338)
5. Held to maturity investment	255		-	-
VI. Other long-term assets	260		22,259,378	31,163,126
1. Long-term prepaid expenses	261	V.8b	22,259,378	31,163,126
2. Deferred income tax assets	262		-	-
3. Long-term replacement equipment, supplies and spa	263		-	-
4. Other long-term assets	268		-	-
TOTAL ASSET	270		1,668,132,148,424	1,685,696,277,497

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

Interim Balance Sheet (Cont.)

CAPITAL SOURCE		Cod e	Explanat ion	Ending Balance	Beginning Balance
C - LIABILITIES PAYABLE		300		123,743,229,640	128,139,839,610
I. Short-term debt		310		123,743,229,640	128,139,839,610
1. Short-term trade payables		311	V.13	1,124,723,591	6,073,280,479
2. Short-term advance payment buyer		312		-	-
3. Taxes and other payments to the State		313	V.14	7,840,618	6,016,462
4. Payable to workers		314		202,684,802	376,678,179
5. Short-term payable expenses		315	V.15	16,835,019,188	13,974,060,840
6. Short-term internal payables		316		-	-
7. Payable according to construction contract progress		317		-	-
8. Short-term unearned revenue		318		-	-
9. Other short-term payables		319	V.16	75,947,865,614	75,931,270,000
10. Short-term loans and finance leases		320	V.17	29,625,095,827	31,778,533,650
11. Provision for short-term payables		321		-	-
12. Bonus and welfare fund		322		-	-
13. Price stabilization fund		323		-	-
14. Government bond repurchase transaction		324		-	-
II. Long-term debt		330		-	-
1. Long-term trade payables		331		-	-
2. Long term prepayment buyer		332		-	-
3. Long-term payable expenses		333		-	-
4. Internal payable on working capital		334		-	-
5. Long-term internal payables		335		-	-
6. Long-term unrealized revenue		336		-	-
7. Other long-term payables		337		-	-
8. Long-term loans and financial leases		338		-	-
9. Convertible bonds		339		-	-
10. Preferred stock		340		-	-
11. Deferred income tax payable		341		-	-
12. Long-term payables provision		342		-	-
13. Science and Technology Development Fund		343		-	-

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

Interim Balance Sheet (Cont.)

CAPITAL SOURCE	Cod e	Explanat ion	Ending Balance	Beginning Balance
D - OWNER'S EQUITY	400		1,544,388,918,784	1,557,556,437,887
I. Equity	410	V.18	1,544,388,918,784	1,557,556,437,887
1. Owner's equity	411		1,311,056,500,000	1,311,056,500,000
- Common shares with voting rights	411a		1,311,056,500,000	1,311,056,500,000
- Preferred stock	411b		-	-
2. Capital surplus	412		(395,300,000)	(395,300,000)
3. Bond conversion option	413		-	-
4. Other owners' equity	414		-	-
5. Treasury stock	415		-	-
6. Asset revaluation difference	416		-	-
7. Exchange rate difference	417		-	-
8. Development investment fund	418		-	-
9. Enterprise Reorganization Support Fund	419		-	-
10. Other equity funds	420		-	-
11. Undistributed profit after tax	421		233,727,718,784	246,895,237,887
- Undistributed profit after tax accumulated to the end of the period	421a		246,895,237,887	212,781,966,422
- Undistributed profit this period	421b		(13,167,519,103)	34,113,271,465
12. Source of capital for basic construction investment	422		-	-
II. Other funding sources and funds	430		-	-
1. Funding sources	431		-	-
2. Funds for forming fixed assets	432		-	-
TOTAL CAPITAL	440		1,668,132,148,424	1,685,696,277,497

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Prepared on 23 May, 2025

Director



Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

INTERIM INCOME STATEMENT

The first 6 months of the fiscal year ending December 31, 2024

Unit: VND

Accumulated from the beginning of the
year to the end of this period

INDICATORS	Code	Explanation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
1. Sales and service revenue	01	VI.1	33,117,279,215	22,695,683,188
2. Revenue deductions	02	VI.1	-	3,028,000
3. Net revenue from sales and services	10	VI.1	33,117,279,215	22,692,655,188
4. Cost of goods sold	11	VI.2	32,299,544,827	17,608,603,626
5. Gross profit from sales and service provision	20		817,734,388	5,084,051,562
6. Financial revenue	21	VI.3	5,000,186,282	10,184,796,592
7. Financial costs	22	VI.4	16,989,674,459	9,569,685,937
Including: interest expense	23		3,034,589,990	3,985,973,154
8. Cost of sales	25	VI.5	150,550,707	1,380,027,624
9. Business management costs	26	VI.6	1,812,274,361	1,709,581,859
10. Net operating profit	30		(13,134,578,857)	2,609,552,734
11. Other income	31		-	-
12. Other costs	32	VI.7	32,940,246	229,280,368
13. Other profits	40		(32,940,246)	(229,280,368)
14. Total accounting profit before tax	50		(13,167,519,103)	2,380,272,366
15. Current corporate income tax expense	51	VI.8	-	-
16. Deferred corporate income tax expense	52		-	-
17. Profit after corporate income tax	60		(13,167,519,103)	2,380,272,366

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Prepared on 23 May, 2025



Director

Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

INTERIM CASH FLOW STATEMENT

(By indirect method)

The first 6 months of the fiscal year ending December 31, 2024

Unit: VND

INDICATORS	Code	Explan ation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
I. Cash flow from operating activities				
1. Profit before tax	01		(13,167,519,103)	2,380,272,366
2. Adjustments for the following items:				
- Depreciation of fixed assets and investment real estate	02		5,023,460,818	5,674,321,276
- Provisions	03		14,126,324,313	5,351,483,264
- Exchange rate gains and losses due to revaluation foreign currency monetary items	04		-	-
- Profit and loss from investment activities	05		(5,000,186,282)	(10,113,234,948)
- Interest expense	06		3,034,589,990	3,985,973,154
- Other adjustments	07		-	-
3. Profit from operations before changes in working capital	08		4,016,669,736	7,278,815,112
- Increase, decrease receivables	09		13,888,126,529	(15,234,085,155)
- Increase, decrease inventory	10		19,390,170,174	(17,062,592,409)
- Increase, decrease payables	11		(5,254,130,495)	4,311,687,717
- Increase, decrease prepaid expenses	12		29,494,656	225,804,285
- Increase, decrease trading securities	13		-	-
- Interest paid	14		(23,631,642)	(2,001,730)
- Corporate income tax paid	15		-	(1,335,636,262)
- Other income from operating activities	16		-	-
- Other expenses for business activities	17		-	-
Net cash flow from operating activities	20		32,046,698,958	(21,818,008,442)
II. Cash flow from investing activities				
1. Money spent on purchasing and constructing fixed assets and other long-term assets	21		-	(90,000,000)
2. Proceeds from liquidation and sale of fixed assets and other long-term assets	22		-	-
3. Money spent on lending, buying debt instruments other units	23		(10,000,000,000)	-
4. Proceeds from loan recovery, resale of debt instruments other units	24		5,000,000,000	-
5. Money spent on investment in other entities	25		(35,263,500,000)	(29,290,000,000)
6. Proceeds from capital investment in other entities	26		-	19,400,000,000
7. Interest income, dividends and profits	27		5,000,186,282	113,234,948
Net cash flow from investing activities	30		(35,263,313,718)	(9,866,765,052)

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

INTERIM FINANCIAL STATEMENTS

The first 6 months of the fiscal year ending December 31, 2024

"Interim cash flow statement (continued)"

INDICATORS	Code	Explan ation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
III. Cash flow from financing activities				
1. Proceeds from issuing shares, receiving capital contributions owner	31		-	-
2. Money returned to owners, buyback issued company shares	32		-	-
3. Proceeds from borrowing	33		-	-
4. Loan principal repayment	34		(2,153,437,823)	(579,635,855)
5. Lease principal repayment	35		-	-
6. Dividends, profits paid to owners	36		-	-
Net cash flow from financing activities	40		(2,153,437,823)	(579,635,855)
Net cash flow during the period	50		(5,370,052,583)	(32,264,409,349)
Cash and cash equivalents at the beginning of the year	60	V.1	6,404,911,296	34,705,706,149
Impact of Foreign Exchange Rate Fluctuations on Currenc	61		-	-
Cash and cash equivalents at the end of the period	70	V.1	1,034,858,713	2,441,296,800

Prepared by


 Nguyen Minh Hoa

Chief Accountant


 Le Thi Viet Ha

Prepared on 23 May, 2025

Director



 Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

NOTES TO INTERIM FINANCIAL STATEMENTS

First 6 months of the fiscal year ending December 31, 2024

I. CHARACTERISTICS OF COMPANY OPERATIONS

1. **Form of capital ownership** : Joint Stock Company

2. **Business Field** : Medical equipment and medical testing chemicals

3. **Company Overview**

American VietNameese Biotech INC was established under Business Registration Certificate No. 3800237998 issued by the Department of Planning and Investment of Ho Chi Minh City for the first time on August 26, 2002. During its operation, the Company has changed its business registration certificate 23 times. The 23rd change in the business registration certificate of the joint stock company was issued on August 5, 2024.

Charter capital according to the 23rd Business Registration Certificate: VND 1,311,056,500,000

Actual contributed capital as of June 30, 2024: VND 1,311,056,500,000

Headquarters:

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

Phone: 0651.3.889034

Fax: 0651.3.889032

Tax code: 3 8 0 0 2 3 7 9 9 8

4. **Business sector** :

- Retail of medicines, medical equipment, cosmetics and hygiene products in specialized stores
(Details: pharmaceutical business, buying and selling medical equipment, medical testing tools and chemicals);
 - Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments
(Details: Manufacturing medical testing equipment);
 - Production of drugs, pharmaceutical chemicals and medicinal materials
(Details: Production and trading of vaccines and medical biological products);
 - Production of cosmetics, soaps, detergents, polishes and cleaning products; Agents, brokers, auctioneers (Details: Agents for consignment of goods, production of plastic products);
 - Real estate business, land use rights owned, used or rented
(Details: Real estate business);
 - Water exploitation, treatment and supply; Drainage and wastewater treatment; Scrap recycling; Pollution treatment and other waste management activities;
 - Other professional, scientific and technological activities not elsewhere classified
(Details: Technology transfer);
 - Other business lines specifically specified in the Business Registration Certificate./.
- Main business activities: Trading in medical equipment and medical testing chemicals.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**5. Normal production and business cycle**

Normal business production cyclecompany no more than 12 months.

6. Statement on comparability of information in financial statements

The interim financial statements for the first 6 months of the fiscal year ending December 31, 2024 are fully consistent and comparable with the interim financial statements for the first 6 months of the fiscal year ending December 31, 2023 and the financial statements for the fiscal year ending December 31, 2023.

7. Staff.

At the end of the accounting period, the Company had 17 employees working (the number at the beginning of the year was 17 employees).

8. Business structure:***Subsidiary***

Company Name	Head office Totalress	Ownership ratio	Voting ratio	Main business lines
Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du extended street, Nong Trang ward, Viet Tri city, Phu Tho province, Vietnam	83.33%	83.33%	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment
Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Park, Nam Son Commune, Ba Che District, Quang Ninh Province	99.00%	99.00%	Manufacture of medicines, pharmaceutical chemicals and pharmaceutical materials. Manufacture of ovens, furnaces and kilns
Kyoto Bai Chay Clinic Joint Stock Company	Group 4, Zone 4, Bai Chay Ward, Ha Long City, Quang Ninh, Vietnam	98.00%	98.00%	General and specialized clinics
Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park – Phase 1, Dong Phu Commune, Chau Thanh District, Hau Giang Province, Vietnam	98.00%	98.00%	Manufacture of ovens, furnaces and furnaces
Vietnam National Software Production Joint Stock Company	No. 36 BT5 Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hoang Mai District, Hanoi, VN	98.00%	98.00%	Computer programming
Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh, Kien Hung Ward, Ha Dong District, Hanoi City	98.00%	98.00%	General, specialist and dental clinics
Hoa Binh Clinic Joint Stock Company	No. 83 Cu Chinh Lan Street, Dong Tien Ward, Hoa Binh City, Hoa Binh Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du extended street, Nong Trang ward, Viet Tri city, Phu Tho province	98.00%	98.00%	General, specialist and dental clinics
Gia Lam High-Tech Clinic Joint Stock Company	18 BT5 Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Can Tho Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Ninh Kieu District, Can Tho City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Hau Giang Clinic	No. 16, 1st Floor, Street No. 14, Area	98.00%	98.00%	General, specialist and

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

Joint Stock Company	4, Ward III, Vi Thanh City, Hau Giang Province			dental clinics
Medicare Soc Trang Clinic Joint Stock Company	1st Floor, No. 438 Le Duan Street, Hamlet 4, Ward 4, Soc Trang City, Soc Trang Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Nga Bay Clinic Joint Stock Company	No. 222, 30/4 Street, Area 5, Lai Hieu Ward, Nga Bay City, Hau Giang Province	98.00%	98.00%	General, specialist and dental clinics
Leopard Solutions Joint Stock Company	No. 34, Road 79, Dinh Hamlet, Tan Phu Trung Commune, Cu Chi District, Ho Chi Minh City, Vietnam	75.00%	75.00%	Computer programming
Golab Vung Tau Laboratory Center Joint stock Company	No. 745 Vo Van Kiet, Long Tam Ward, Ba Ria City, Ba Ria Vung Tau Province	98.00%	98.00%	General, specialist and dental clinics

Indirectly owned subsidiaries:

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Famicare Thu Duc Joint stock Company	28 Hien Vuong, Hiep Phu Ward, Thu Duc City, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics
Medicare Nha Be Clinic Joint Stock Company	568 Le Van Luong Hamlet 3, Phuoc Kien Commune. Nha Be District, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics

Associate company:

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Golab Phap Van Testing Center Joint Stock Company	Floor 1, Lot BT 5, No. 18 New Urban Area, Phap Van – Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi, Vietnam	35%	35%	General, specialist and dental clinics
Famicare Phap Van Joint Stock Company	Floor 1, Lot BT 5, No. 17 New Urban Area, Phap Van – Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi, Vietnam	35%	35%	General, specialist and dental clinics
Golab Go Vap Testing Center Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son Street, Ward 4, Go Vap District, Ho Chi Minh City.	35%	35%	General, specialist and dental clinics

II. FISCAL YEAR, CURRENCY USED IN ACCOUNTING**1. Fiscal year**

The Company's fiscal year begins on January 1 and ends on December 31 of each year.

2. Currency used in accounting

The currency used in accounting is Vietnamese Dong (VND) because revenue and expenditure are mainly made in VND.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

III. ACCOUNTING STANDARDS AND REGIMES APPLIED

1. Applicable accounting standards

The Company applies accounting standards, Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC and circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing and presenting Financial Statements.

2. Statement on compliance with accounting standards and accounting regimes

The Board of Directors ensures that it has complied with the requirements of accounting standards, the Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC as well as circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing Financial Statements.

IV. ACCOUNTING POLICIES APPLIED

1. Basis for preparing financial statements

Financial statements are prepared on the accrual basis of accounting (except for information relating to cash flows).

Users of these interim financial statements should read them together with the interim consolidated financial statements of the Company and its subsidiaries ("the Group") for the six-month period ended 31 December 2024 in order to obtain full information on the financial position, results of operations and cash flows of the Group as a whole.

2. Cash and cash equivalents

Cash includes cash on hand, demand deposits, monetary gold used for value storage purposes, excluding gold classified as inventories used as raw materials for the production of products or goods for sale.

Cash equivalents are short-term investments with a maturity of no more than three months from the date of purchase, which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

3. Financial investments

Loans

Loans are measured at cost less allowance for doubtful debts. Allowance for doubtful debts on loans is made based on the expected level of loss that may occur.

Investments in subsidiaries, joint ventures and associates

Subsidiary

A subsidiary is an enterprise controlled by the Enterprise. Control is achieved when the Enterprise has the power to govern the financial and operating policies of an investee enterprise so as to obtain benefits from its activities.

Investments in subsidiaries and associates are initially recorded at cost, including the purchase price or capital contribution plus costs directly related to the investment. In case of investment in non-monetary

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

assets, the cost of the investment is recorded at the fair value of the non-monetary assets at the time of acquisition.

Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of shares increased, not the value of the shares received/recorded at par value.

Provision for losses on investments in subsidiaries and associates is made when the subsidiary or associate suffers a loss, with the provision equal to the difference between the actual capital contributions of the parties in the subsidiary, joint venture or associate and the actual equity multiplied by the ratio of the Enterprise's capital contribution to the total actual capital contributions of the parties in the subsidiary or associate. If the subsidiary or associate is the subject of the Consolidated Financial Statement, the basis for determining the provision for losses is the Consolidated Financial Statement.

Increase or decrease in the provision for investment losses in subsidiaries and associates that must be set up at the end of the fiscal year is recorded in financial expenses.

Investments in equity instruments of other entities

Investments in equity instruments of other entities include investments in equity instruments but the Enterprise does not have control, joint control or significant influence over the investee.

Investments in equity instruments of other entities are initially recorded at cost, including the purchase price or capital contribution plus direct costs related to the investment. Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of Totalitional shares, not recording the value of shares received/recorded at par value (except for state-owned enterprises in accordance with current regulations of law).

Provision for losses on investments in equity instruments of other entities is made as follows:

- For investments in listed shares or for which the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the reporting date, provisions are made based on the loss of the investee with the provision equal to the difference between the actual capital contribution of the parties at other entities and the actual equity multiplied by the capital contribution ratio of the Enterprise compared to the total actual capital contribution of the parties at other entities.

Increases and decreases in the provision for investment losses in equity instruments of other entities that need to be set up at the end of the fiscal year are recorded in financial expenses.

4. Accounts Receivable

Accounts receivable are stated at carrying amount less allowance for doubtful debts.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

The classification of receivables as trade receivables and other receivables is carried out according to the following principles:

- Trade receivables reflect commercial receivables arising from purchase-sale transactions between the company and buyers who are independent entities, including receivables from export sales entrusted to other entities.
- Other receivables reflect non-commercial receivables not related to purchase and sale transactions.

Provision for doubtful debts is made for each doubtful debt based on the age of overdue debts or the expected level of loss that may occur, specifically as follows:

- For overdue receivables:
 - 30% of the value for overdue receivables from 6 months to less than 1 year.
 - 50% of the value for overdue receivables from 1 year to less than 2 years.
 - 70% of the value for receivables overdue from 2 years to less than 3 years.
 - 100% of the value for receivables 3 years or more old.
- For receivables that are not overdue but are unlikely to be recovered: establish provisions based on expected loss level.

5. Inventory

Inventories are goods and are stated at the lower of cost and net realizable value. The cost of inventories is determined including the cost of purchase and other directly relevant costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories are valued at cost using the weighted average method and accounted for using the perpetual inventory method.

Provision for inventory devaluation is established for each inventory item whose original cost is greater than its net realizable value. For unfinished services, provision for devaluation is calculated for each type of service with a separate price. Increases and decreases in the balance of provision for devaluation of inventory required to be established at the end of the fiscal year are recorded in cost of goods sold.

6. Prepaid expenses

Prepaid expenses include actual expenses that have been incurred but are related to the results of production and business activities of many accounting periods. The company's prepaid expenses are the cost of tools and equipment.

Tools, instruments

Tools and equipment put into use are allocated to expenses using the straight-line method with an allocation period of no more than 03 years.

7. Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets includes all costs incurred by the company to acquire the fixed assets up to the time the assets are ready for use. Expenses incurred after initial recognition are only recorded as an increase in the cost of fixed assets if it is certain that these costs will increase future economic benefits from the use of the

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

assets. Expenses incurred that do not satisfy the above conditions are recorded as production and business expenses in the period.

When tangible fixed assets are sold or disposed of, their cost and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is recognized as income or expense in the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives. The depreciation years for various types of Tangible Fixed Assets are as follows:

Type of fixed asset	No. 5
Machinery and equipment	06-10

8. Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated depreciation.

The original cost of intangible fixed assets includes all costs that Company must be spent to acquire fixed assets up to the time the asset is ready for use. Expenditures relating to intangible fixed assets incurred after initial recognition are recognised as expenses in the period in which they are incurred, unless they are associated with a specific intangible fixed asset and result in an increase in the economic benefits derived from the asset.

Intangible fixed assets of Company include:

Software program

Costs relating to computer software programs that are not part of the related hardware are capitalized. The cost of computer software is the total cost incurred by the Company up to the date the software is put into use. Computer software is amortized on a straight-line basis over 10-20 years.

9. Cost of unfinished basic construction

Construction in progress reflects directly related costs (including including interest expenses related to the Company's accounting policies) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to repairs of fixed assets in progress. These assets are recorded at original cost and not depreciated

10. Accounts Payable and Accrued Expenses

Liabilities and accruals are recognized for amounts to be paid in the future for goods and services received. Accruals are recognized based on reasonable estimates of the amounts to be paid.

The classification of payables as trade payables, accrued expenses, internal payables and other payables is carried out according to the following principles:

- Trade payables reflect commercial payables arising from transactions of purchasing goods, services, assets and the seller is an independent entity of the company, including payables when importing through consignees.
- Payable expenses reflect amounts payable for goods and services received from sellers or provided to buyers but not yet paid due to lack of invoices or insufficient accounting records and documents, and amounts payable to employees for leave wages, production and business expenses that must be accrued in advance.
- Other payables reflect non-commercial payables not related to the purchase, sale or provision of goods and services.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

11. Equity

Owner's equity

Owner's equity is recorded according to the actual capital contributed by shareholders.

Capital surplus

Share capital surplus is recorded as the difference between the issue price and the par value of shares when first issued, Totalitional issued or the difference between the reissue price and the book value of treasury shares. Direct costs related to the Totalitional issuance of shares and reissuance of treasury shares are recorded as a decrease in share capital surplus.

Other owners' equity

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

12. Profit distribution

Profit after corporate income tax is distributed to shareholders after setting aside funds according to the Company's Charter as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to shareholders takes into account non-cash items in undistributed earnings that may affect cash flows and the ability to pay dividends. Gains from revaluation of assets contributed as capital, gains from revaluation of monetary items, financial instruments and other non-monetary items.

Other funds

Funds are set aside and used in accordance with the Company Charter and the Resolution of the Annual Shareholders' Meeting.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

13. Revenue and income recognition

a) Sales revenue

Revenue from the sale of goods is recognized when all of the following conditions are simultaneously satisfied:

- The company has transferred to the buyer the significant risks and rewards of ownership of the products or goods.
- The Company no longer holds title to the goods or control over the goods.
- Revenue is determined with relative certainty. When the contract stipulates that the buyer has the right to return the purchased products or goods under specific conditions, revenue is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the products or goods (except in cases where the customer has the right to return the goods in exchange for other goods or services).
- The Company has obtained or will obtain economic benefits associated with the sale transaction.
- Identify the costs associated with a sales transaction

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

b) Service revenue

Revenue from a service transaction is recognised when the outcome of the transaction can be measured reliably. In cases where the service is performed over several periods, revenue is recognised in each period based on the results of the work completed at the end of the accounting period. The outcome of a service transaction is recognised when all of the following conditions are met:

- Revenue is measured reliably. When a contract provides that the buyer has the right to return the services purchased under specific conditions, revenue is recognized only when the specific conditions no longer exist and the buyer has no right to return the services provided.
- It is possible to obtain economic benefits from the transaction of providing that service.
- Determine the portion of work completed as of the end of the fiscal year.
- Identify the costs incurred for the transaction and the costs to complete the transaction to provide that service.

c) Interest

Interest is recognized on an accrual basis, determined on the deposit account balance and the actual interest rate for each period.

d) Dividends and profits distributed

Dividends and profits distributed are recognized when the company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked by the number of shares increased, not recorded at par value of shares received.

14. Cost of goods sold.

Cost of goods sold during the year is recorded in accordance with revenue generated during the period and ensures compliance with the principle of prudence.

1. Borrowing costs

Borrowing costs include interest and other costs incurred in connection with borrowing.

2. Corporate income tax

Current income tax

Current income tax is the tax that is calculated on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses as well as adjustments for non-taxable income and losses carried forward.

3. Financial instruments

i. Financial assets

Classification of financial assets

The Company classifies its financial assets into the following groups: financial assets at fair value through the Statement of Business Performance, investments held to maturity, loans and receivables, and available-for-sale financial assets. The classification of these financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Financial assets are recorded at fair value through the Statement of Business Performance

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

Financial assets are classified as measured at fair value through the Statement of Income if they are held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial assets are classified as held for trading securities if:

- Purchased or created primarily for the purpose of resale in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

Held to maturity investments

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that the Company has the intention and ability to hold to maturity.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments and are not listed on an active market.

Financial assets available for sale

Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or that are not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

Initial book value of financial assets

Financial assets are recognised at the date of acquisition and derecognised at the date of sale. At the time of initial recognition, financial assets are measured at their purchase price/issuance costs plus any other costs directly attributable to the acquisition or issue of the financial asset.

ii. Financial liabilities

The Company classifies financial liabilities into groups: financial liabilities recorded at fair value through the Income Statement, financial liabilities determined at amortized cost. The classification of financial liabilities depends on the nature and purpose of the financial liability and is determined at the time of initial recognition.

Financial liabilities are recorded at fair value through the Statement of Income.

A financial liability is classified as measured at fair value through the Statement of Income if it is held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial liabilities are classified as held for trading securities if:

- Issued or created primarily for the purpose of repurchasing in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

Financial liabilities are measured at amortized cost.

Financial liabilities are measured at amortised cost, which is the amount at which the financial liability is initially recognised minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

The effective interest method is a method of calculating the amortized cost of a financial liability or group of financial liabilities and allocating interest income or expense over the relevant period. The effective interest rate is the rate at which estimated future cash flows that will be paid or received over the expected life of the financial instrument or, if appropriate, shorter, are discounted to the net present carrying amount of the financial liability.

Initial book value of financial liability

At initial recognition, financial liabilities are measured at issue price plus any costs directly attributable to the issue of the financial liability.

iii. Equity instruments

An equity instrument is a contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

4. Related parties

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

Transactions with related parties during the period are presented in note VII.1.

V. TOTALITIONAL INFORMATION FOR ITEMS PRESENTED IN THE INTERIM BALANCE SHEET**1. Cash and cash equivalents**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Cash	998.128.923	4,763,319,595
Non-term bank deposits	36,729,790	1,641,591,701
Total	<u>1,034,858,713</u>	<u>6,404,911,296</u>

2. Short-term receivables of client

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	<u>Value</u>	<u>Preventive</u>	<u>Value</u>	<u>Preventive</u>
Ha Cuong Trading Investment Company Limited	-	-	6,747,955,200	-
Japan Medical Equipment Co., Ltd.	5,984,880,000	-	8,642,123,175	-
G7 High Technology Joint Stock Company	10,000,000,000	-	18,370,000,000	-
Lou Investment Joint Stock Company	26,422,356,460	-	-	-
Other customers	7,562,273,261	(246,615,129)	5,771,256,201	(75,375,285)
Total	<u>49,969,509,721</u>	<u>(246,615,129)</u>	<u>39,531,334,576</u>	<u>(75,375,285)</u>

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**3. Short-term seller advance**

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
<i>Advance payment to related parties</i>	23,000,000,000	-	46,000,000,000	-
Viet Tri Clinic Joint Stock Company		-		-
(*)	23,000,000,000		46,000,000,000	
<i>Prepay to other sellers</i>	72,646,903,965	-	67,153,578,000	-
Can Tho Environment and Test Center				
Joint stock Company(*)	20,000,000,000	-	20,000,000,000	-
Japan Kanpeki Joint stock Company	4,978,974,137	-	-	-
High-Tech Medical Environment				
Company Limited (*)	2,099,000,000	-	2,099,000,000	-
Nha Trang Medical Hi-Tech		-		-
Application Joint Stock Company (*)	45,000,000,000		45,000,000,000	
Other suppliers	568,929,828	-	54,578,000	-
Total	95,646,903,965	-	113,153,578,000	-

(*) These are advances for the purpose of purchasing machinery, software, and medical equipment for production and business activities. However, due to the deadline for providing the machines, the parties have terminated the contract and returned the money. Up to now, the Company has recovered the entire amount of the advance.

4. Short-term loan receivable

	Ending Balance	Beginning Balance
<i>Receivable from related parties (*)</i>	5,000,000,000	-
Famicare Phap Van Joint Stock Company	2,500,000,000	-
Golab Phap Van Test Center Joint Stock Company	2,500,000,000	-
Total	5,000,000,000	-

(*) These are capital support amounts that have been fully recovered by July 29, 2024.

5. Other short-term receivables

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
<i>Receivables from other organizations and individuals</i>	679,209,284	-	514,885,909	-
Social insurance	-	-	1,212,112	-
Advance	368,995,665	-	181,620,350	-
Bet, deposit	310,213,619	-	332,053,447	-
Total	679,209,284	-	514,885,909	-

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**6. Bad debt**

	Ending Balance		Beginning Balance	
	Original price	Recoverable value	Original price	Recoverable value
Hau Giang Tuberculosis and Lung Hospital	35,168,802	-	35,168,802	-
Phu Tho Provincial General Hospital	25,420,002	12,710,001	25,420,002	12,710,001
Gia Rai Town Medical Center	27,496,482	-	27,496,482	-
Central Lung Hospital	171,239,844	-	-	-
Total	259,325,130	12,710,001	88,085,286	12,710,001

7. Inventory

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
Goods (*)	141,582,441,474	-	160,972,611,648	-
Total	141,582,441,474	-	160,972,611,648	-

(*) Inventory is software with a value of 140,080,690,416 VND up to now, sold and debt recovered.

8. Prepaid expenses**a. Short-term prepaid expenses**

	Ending Balance	Beginning Balance
Tools and equipment	9,340,912	-
Other short-term prepaid expenses	-	29,931,820
Total	9,340,912	29,931,820

b. Long-term prepaid expenses

	Ending Balance	Beginning Balance
Other long-term prepaid expenses	22,259,378	31,163,126
Total	22,259,378	31,163,126

9. Tangible fixed assets

	Machinery and equipment	Total
Original price		
Beginning Balance	64,268,202,914	64,268,202,914
Liquidation, sale	(7,350,000,000)	(7,350,000,000)
Ending Balance	56,918,202,914	56,918,202,914
<i>In there: Fully depreciated but still in use</i>	7,392,200,000	7,392,200,000
Depreciation value		
Beginning Balance	26,000,972,099	26,000,972,099
Depreciation during the period	2,975,789,440	2,975,789,440
Liquidation, sale	(428,750,000)	(428,750,000)
Ending Balance	28,548,011,539	28,548,011,539
Residual value		
Beginning Balance	38,267,230,815	38,267,230,815
Ending Balance	28,370,191,375	28,370,191,375

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

Some tangible fixed assets are machinery and equipment with original cost and residual value of VND 38,916,611,293 and 26,906,861,360 VND is being mortgaged for the loan at Viet Capital Commercial Joint Stock Bank.

10. Intangible fixed assets

	<u>Software program</u>	<u>Total</u>
Original price		
Beginning Balance	40,953,427,745	40,953,427,745
Purchase during the period	-	-
Ending Balance	<u>40,953,427,745</u>	<u>40,953,427,745</u>
<i>In there:</i>		
Fully depreciated but still in use	-	-
Depreciation value		
Beginning Balance	16,526,054,590	16,526,054,590
Depreciation during the period	2,047,671,378	2,047,671,378
Ending Balance	<u>18,573,725,968</u>	<u>18,573,725,968</u>
Residual value		
Beginning Balance	24,427,373,155	24,427,373,155
Ending Balance	<u>22,379,701,777</u>	<u>22,379,701,777</u>

The company's intangible fixed assets are the Pacs Software System:

This is a RIS – PACS medical image storage and transmission system that has been installed synchronously by the Company to serve medical examination and treatment, image diagnosis, and accompanying hardware installed at medical facilities (General Hospitals, Medical Centers of provinces/cities) according to the Agreement on cooperation in installation, trial use or business cooperation between the Company and medical facilities and has been accepted by the medical facilities and put into operation.

In some hospitals, there has been revenue, but due to the lack of specific and unified instructions on payment for technical services of diagnostic imaging based on the PACS system, the Company still does not have enough reliable basis to fully determine the economic benefits that will be obtained from this leasing and business cooperation. Currently, the Company is mainly collecting fees for providing maintenance services, maintenance of machinery and equipment as well as 24/24 technical support fees for the PACS system.

11. Construction in progress

	<u>Beginning Balance</u>	<u>Costs incurred during the period</u>	<u>Transferred to fixed assets during the period</u>	<u>Ending Balance</u>
Fixed asset purchases	26,588,372,787	-	-	26,588,372,787
Machine systems in hospitals	2,953,624,566	-	-	2,953,624,566
PACS System at Medical Centers	23,634,748,221	-	-	23,634,748,221
Total	<u>26,588,372,787</u>	<u>-</u>	<u>-</u>	<u>26,588,372,787</u>

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**12. Long-term financial investment****a, Investment in Subsidiaries**

	Ending Balance		Beginning Balance	
	Original price	Preventive	Original price	Preventive
<i>Investment in subsidiaries</i>	<i>1,289,040,000,000</i>	<i>(27,365,598,807)</i>	<i>1,289,040,000,000</i>	<i>(13,410,514,338)</i>
Viet My Hospital Investment Joint Stock Company (Ownership ratio 83.33%)	250,000,000,000	(12,461,465,473)	250,000,000,000	(8,429,639,324)
Ha Long Kyoto Technology Development Joint Stock Company (Ownership ratio 99%)	108,900,000,000	(5,240,889,920)	108,900,000,000	(58,454,016)
Kyoto Bai Chay Clinic Joint Stock Company (Ownership ratio 98%)	49,000,000,000	(1,135,899,440)	49,000,000,000	(1,019,226,739)
Song Hau New Technology Application Research Joint Stock Company (Ownership ratio 98%)	147,000,000,000	-	147,000,000,000	-
Vietnam National Software Production Joint Stock Company (Ownership ratio 98%)	29,400,000,000	-	29,400,000,000	-
Ha Dong Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(981,100,857)
Hoa Binh Clinic Joint Stock Company (Ownership ratio 98%)	122,500,000,000	(6,693,196,086)	122,500,000,000	(1,037,005,209)
Viet Tri Clinic Joint Stock Company (Ownership ratio 98%)	106,820,000,000	-	106,820,000,000	(3,475,927)
Gia Lam High-Tech Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(668,216,290)	77,420,000,000	(759,111,361)
Medicare Can Tho Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(753,461,680)	77,420,000,000	(434,480,816)
Medicare Hau Giang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(11,799,211)	77,420,000,000	(164,978,524)
Medicare Soc Trang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(250,096,236)	77,420,000,000	(403,451,229)
Medicare Nga Bay Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	-
Leopard Solutions Joint Stock Company (Ownership ratio 75%)	6,000,000,000	-	6,000,000,000	-
Golab Vung Tau Laboratory Center Joint stock Company (Ownership ratio 98%)	4,900,000,000	(150,574,471)	4,900,000,000	(119,590,336)
Total	1,289,040,000,000	(27,365,598,807)	1,289,040,000,000	(13,410,514,338)

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**b, Investment in joint ventures and associates, other investments**

	Ending Balance		Actual capital contribution ratio	Beginning Balance	
	Original price	Preventive		Original price	Preventive
<i>Investment in joint ventures and associates</i>	<i>31,500,000,000</i>	<i>(39,131)</i>		-	-
Golab Phap Van Test Center Joint Stock Company (*)	10,500,000,000	(30,793)	35%	-	-
Famicare Phap Van Joint Stock Company	10,500,000,000	(8,338)	35%	-	-
Golab Go Vap Test Center Joint Stock Company	10,500,000,000	-	35%	-	-
<i>Investing in other entities</i>	<i>3,763,500,000</i>	<i>(27,150,344)</i>		-	-
Nghe An Clinic Joint Stock Company	1,000,000,000	(300,000)	3%	-	-
Huu nghi Medicare Clinic joint stock company	1,763,500,000	(16,096,529)	6%	-	-
Medicare Ninh Binh Clinic Joint Stock Company	1,000,000,000	(10,753,815)	3%	-	-
Total	35,263,500,000	(27,189,475)		-	-

(*) Famicare Phap Van Joint Stock Company was established but has not yet formed, or has only insignificantly formed, assets to support its business operations.

13. Short-term trade payables

	Ending Balance	Beginning Balance
TSG Trading and Service business Company limited	-	4,902,721,200
Phuong Dong Technology Engineering Joint Stock Company	-	232,965,920
Vietnam Medical Technology Company Limited	104,750,000	104,750,000
Branch of Duy Minh Equipment Company Limited	650,444,922	650,444,922
JWB CO.,LTD	214,478,120	-
Other suppliers	155,050,549	182,398,437
Total	1,124,723,591	6,073,280,479

14. Taxes and other payments to the State

	Beginning Balance	Amount payable during the period	Amount actually paid during the period	Ending Balance
VAT on imported goods	-	10,723,906	(10,723,906)	-
Corporate income tax	-	-	-	-
Personal income tax	6,016,462	18,487,513	(16,663,357)	7,840,618
Other taxes	-	6,000,000	(6,000,000)	-
Total	6,016,462	35,211,419	(33,387,263)	7,840,618

The Company's tax settlement is subject to examination by the tax authorities. Since the application of tax laws and regulations to various types of transactions is susceptible to varying interpretations, the

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

tax amounts presented in the Financial Statements may be subject to change at the discretion of the tax authorities.

Value Totalled Tax

The Company pays value Totalled tax by the deduction method. Value Totalled tax rates are as follows:

- Revenue from sales of medical supplies and equipment	5%
- Revenue from providing testing, screening and imaging services in conjunction with hospitals	Non-taxable
- Other activities	8%, 10%

Corporate income tax

The company must pay corporate income tax on taxable income at a rate of 20%.

Other taxes

The company declares and pays according to regulations.

15. Short-term payable expenses

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Interest expense payable	16,835,019,188	13,824,060,840
Other short-term payable expenses	-	150,000,000
Total	<u>16,835,019,188</u>	<u>13,974,060,840</u>

16. Other short-term payables

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Social insurance	13,750,256	-
Health insurance	316,528	-
Unemployment insurance	2,003,032	-
Dividends payable (*)	75,924,090,000	75,924,090,000
Other short-term payables	7,705,798	7,180,000
Total	<u>75,947,865,614</u>	<u>75,931,270,000</u>

(*)The 2019 dividend must be paid to shareholders according to the shareholder list as of January 12, 2021. Resolution No. 2502/NQ-HĐQT dated February 25, 2025 of the Board of Directors on changing the time for paying dividends in 2019, accordingly the time for paying dividends is as follows: Payment of the first installment on January 28, 2026; Payment of the second installment on July 28, 2026.

Reason for change: The company is expanding its production and business activities and investing in equipment and machinery for important projects. To ensure progress, the company uses available capital to order necessary equipment.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**17. Short-term loans and finance leases**

	Ending Balance		Beginning Balance	
	Value	Number of debtors	Value	Number of debtors
Short term bank loans	29,625,095,827	29,625,095,827	31,778,533,650	31,778,533,650
<i>An Binh Commercial Joint</i>				
<i>Stock Bank - Hanoi Branch</i>	-	-	155,368,358	155,368,358
<i>BVBank (*)</i>	29,625,095,827	29,625,095,827	31,623,165,292	31,623,165,292
Total	29,625,095,827	29,625,095,827	31,778,533,650	31,778,533,650

(*) Loan under Credit Contract No. 0041900059900 dated November 28, 2019; Amendment and Supplement Agreement dated July 6, 2021 regarding adjustment of the principal repayment schedule. Loan amount: VND 40,000,000,000; Purpose of the loan: Purchase of medical machinery and equipment for production and business operations; Interest rate: 11.5% per annum; Loan term: 48 months. Collateral: medical machinery and equipment under Movable Asset Mortgage Contract No. 0041900060000 dated November 28, 2019.

As of the issuance date of this report, the above loan is overdue. The extension request period stated in Official Letter No. 05/2024/CV-AMV of the Company was October 2024, and it was approved by BVBank in Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of now, the Company has not yet fully repaid the aforementioned principal amount and is continuing to work with the Bank to request an extension.

Details of short-term loans incurred during the period as follows:

	Beginning Balance	Amount of loan incurred during the period	Loan amount repaid during the year	Ending Balance
<i>An Binh Commercial Joint</i>				
<i>Stock Bank - Hanoi Branch</i>	155,368,358	-	(155,368,358)	-
<i>BVBank</i>	31,623,165,292	-	(1,998,069,465)	29,625,095,827
Total	31,778,533,650	-	(2,153,437,823)	29,625,095,827

18. Owner's Equity

	Owner's equity	Capital surplus	Profit after tax not distributed	Total
Last year's opening number	1,311,056,500,000	(395,300,000)	212,781,966,422	1,523,443,166,422
Profit in the previous year	-	-	34,113,271,465	34,113,271,465
Last year ending balance	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
Beginning balance of this year	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
Profit for this period	-	-	(13,167,519,103)	(13,167,519,103)
This period's ending balance	1,311,056,500,000	(395,300,000)	233,727,718,784	1,544,388,918,784

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**Stocks**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Number of shares registered for issuance	131,105,650	131,105,650
Number of shares sold to the public	131,105,650	131,105,650
- Common stock	131,105,650	131,105,650
- Preferred stock	-	-
Number of shares outstanding	131,105,650	131,105,650
- Common stock	131,105,650	131,105,650
- Preferred stock	-	-
Outstanding shares face value: 10,000 VND.		

VI. ADDITIONAL INFORMATION ON ITEMS PRESENTED IN THE INTERIM STATEMENT OF INCOME**1. Revenue from sales and service provision**

	<u>Accumulated from the beginning of the year to the end of this period</u>	
	<u>This year</u>	<u>Last year</u>
Revenue from sales of goods and provision of services	33,117,279,215	22,695,683,188
Revenue deductions	-	(3,028,000)
Returned goods	-	(3,028,000)
Net revenue from sales and services	33,117,279,215	22,692,655,188

2. Cost of goods sold

	<u>Accumulated from the beginning of the year to the end of this period</u>	
	<u>This year</u>	<u>Last year</u>
Cost of goods sold, services provided	32,299,544,827	17,608,603,626
Total	32,299,544,827	17,608,603,626

3. Financial income

	<u>Accumulated from the beginning of the year to the end of this period</u>	
	<u>This year</u>	<u>Last year</u>
Deposit interest, loan interest	186,282	113,234,948
Dividends, profits shared	5,000,000,000	10,000,000,000
Exchange rate difference profit	-	71,561,644
Total	5,000,186,282	10,184,796,592

4. Financial expenses

	<u>Accumulated from the beginning of the year to the end of this period</u>	
	<u>This year</u>	<u>Last year</u>
Interest expense	3,034,589,990	3,985,973,154
Exchange rate difference loss incurred	-	210,788,247
Provision/(Reversal) of investment loss provision	13,955,084,469	5,372,924,536
Total	16,989,674,459	9,569,685,937

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**5. Cost of sales**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>Last year</u>
Employee costs	133,333,332	-
Cost of materials and packaging	-	76,249,796
Outsourcing service costs	17,217,375	126,377,828
Other costs	-	1,177,400,000
Total	150,550,707	1,380,027,624

6. Business management costs

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>Last year</u>
Employee costs	1,164,362,725	1,046,961,823
Office supplies costs	20,590,908	-
Fixed asset depreciation costs	2,996,214	-
Taxes, fees and charges	6,000,000	6,000,000
Provision/(Reversal) of provision for doubtful debts	171,239,844	(21,441,272)
Outsourcing service costs	447,084,670	528,061,308
Other costs	-	150,000,000
Total	1,812,274,361	1,709,581,859

7. Other costs

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>Last year</u>
Depreciation of fixed assets not serving production and business	-	227,695,752
Penalty for late payment of tax and insurance	32,940,246	1,584,616
Total	32,940,246	229,280,368

8. Current corporate income tax expense

Corporate income tax payable during the period is estimated as follows:

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>Last year</u>
Total accounting profit before tax	(13,167,519,103)	2,380,272,366
Adjustments to increase or decrease accounting profit to determine profit subject to corporate income tax:	(3,021,229,189)	(7,824,889,067)
- Increase adjustments	1,978,770,811	2,175,110,933
<i>Depreciation of fixed assets not serving production and business</i>	1,945,830,565	2,173,526,317
<i>Penalty for late payment of tax and insurance</i>	32,940,246	1,584,616
- Adjustments for reduction	(5,000,000,000)	(10,000,000,000)
<i>Dividends, profits shared</i>	(5,000,000,000)	(10,000,000,000)
Taxable income	(16,188,748,292)	(5,444,616,701)
Taxable income	(16,188,748,292)	(5,444,616,701)
Corporate income tax rate	20%	20%
Total Corporate Income Tax payable	-	-

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)**9. Basic earnings per share**

Enterprises do not calculate this indicator on the separate financial statements because according to the provisions of accounting standard No. 30 on "Earnings per share", in case an Enterprise has to prepare both separate financial statements and consolidated financial statements, it only has to present information on earnings per share according to the provisions of this standard on the consolidated financial statements.

10. Expenses by category

	Accumulated from the beginning of the year to the end of this period	
	This year	Last year
Cost of raw materials	20,590,908	76,249,796
Labor costs	1,297,696,057	1,046,961,823
Fixed asset depreciation costs	5,023,460,818	5,674,321,276
Taxes, fees and charges	6,000,000	6,000,000
Provision/(Reversal) of provision for doubtful debts	171,239,844	(21,441,272)
Outsourcing service costs	464,302,045	654,439,136
Other costs	-	1,327,400,000
Total	6,983,289,672	8,763,930,759

VII. OTHER INFORMATION**1. Information about related parties**

Stakeholders of the Enterprise include: key management members, individuals related to key management members and other stakeholders.

A, Transactions and balances with key management members and individuals related to key management members

Key management members include: members of the Board of Directors and members of the Executive Board (Board of Directors, Chief Accountant). Individuals related to key management members are close family members of key management members.

Key Management Members' Compensation:

	Current period	Previous period
Mrs. Dang Nhi Nuong	121,000,000	121,000,000

During the period, the unit did not have any transactions with related parties.

B, Transactions with other related parties

Other related parties to the Enterprise include: subsidiaries, affiliated companies, individuals with direct or indirect voting rights in the Enterprise and close members of their families, enterprises managed by key management personnel and individuals with direct or indirect voting rights of the Enterprise and close members of their families.

Related parties include:	Relationship
Viet My Hospital Investment Joint Stock Company	Subsidiary
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiary
Kyoto Bai Chay Clinic Joint Stock Company	Subsidiary
Song Hau New Technology Application Research Joint Stock Company	Subsidiary
Vietnam National Software Production Joint Stock Company	Subsidiary
Ha Dong Clinic Joint Stock Company	Subsidiary

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

Related parties include:	Relationship
Hoa Binh Clinic Joint Stock Company	Subsidiary
Viet Tri Clinic Joint Stock Company	Subsidiary
Gia Lam High-Tech Clinic Joint Stock Company	Subsidiary
Medicare Can Tho Clinic Joint Stock Company	Subsidiary
Medicare Hau Giang Clinic Joint Stock Company	Subsidiary
Medicare Soc Trang Clinic Joint Stock Company	Subsidiary
Medicare Nga Bay Clinic Joint Stock Company	Subsidiary
Leopard Solutions Joint Stock Company	Subsidiary
Golab Vung Tau Laboratory Center Joint stock Company	Associate company
Huu nghi Medicare Clinic joint stock company	Associate company
Medicare Ninh Binh Clinic Joint Stock Company	Associate company
Golab Vung Tau Testing Center Joint Stock Company	Associate company
Golab Phap Van Testing Center Joint Stock Company	Associate company
Famicare Phap Van Joint Stock Company	Associate company
NGHE AN CLINIC JOINT STOCK COMPANY	Associate company
Golab Go Vap Testing Center Joint Stock Company	Associate company

Transactions with other related parties

The main transactions during the period between the Company and other related parties are as follows:

	Accumulated from the beginning of the year to the end of this period	
	This year	Last year
Viet Tri Clinic Joint Stock Company		
Advance payment for goods purchase receivable	-	50,000,000,000
Advance payment	23,000,000,000	-
Viet My Hospital Investment Joint Stock Company		
Must pay for goods	-	7,350,000,000
Pay for goods	-	7,350,000,000
Song Hau New Technology Application Research Joint Stock Company		
Dividends are distributed	-	10,000,000,000
Kyoto Bai Chay Clinic Joint Stock Company		
Advance payment for goods purchase receivable	-	4,100,000,000
Vietnam National Software Production Joint Stock Company		
Dividend receivable	5,000,000,000	-
Receive dividends and profits	5,000,000,000	-
Pay for goods	-	440,000,000
Golab Phap Van Testing Center Joint Stock Company		
Must collect capital support money	2,500,000,000	-
Famicare Phap Van Joint Stock Company		
Must collect capital support money	2,500,000,000	-

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

	Accumulated from the beginning of the year to the end of this period	
	This year	Last year
Huu nghi Medicare Clinic joint stock company		
Contribution during the period	1,763,500,000	-
Medicare Ninh Binh Clinic Joint Stock Company		
Contribution during the period	1,000,000,000	-
Golab Go Vap Testing Center Joint Stock Company		
Contribution during the period	10,500,000,000	-
Nghe An Clinic Joint Stock Company		
Contribution during the period	1,000,000,000	-

At the end of the accounting period, debts with related parties are presented in detail in notes V.3; V.4 and V.11./.

2. Fair value of financial assets and liabilities

	Book value		Fair value	
	Ending Balance	Beginning Balance	Ending Balance	Beginning Balance
Financial assets				
Cash and cash equivalents	1,034,858,713	6,404,911,296	1,034,858,713	6,404,911,296
Accounts receivable	49,722,894,592	39,455,959,291	49,722,894,592	39,455,959,291
Other receivables	679,209,284	514,885,909	679,209,284	514,885,909
Total	51,436,962,589	46,375,756,496	51,436,962,589	46,375,756,496
Financial liabilities				
Loans and Debts	29,625,095,827	31,778,533,650	29,625,095,827	31,778,533,650
Payable to seller	1,124,723,591	6,073,280,479	1,124,723,591	6,073,280,479
Other payables	92,782,884,802	89,905,330,840	92,782,884,802	89,905,330,840
Total	123,532,704,220	127,757,144,969	123,532,704,220	127,757,144,969

The fair value of financial assets and financial liabilities is reflected at the amount at which the financial instruments could be exchanged in a current transaction between knowledgeable and willing parties.

The Company uses the following methods and assumptions to estimate fair value:

- The fair value of cash and cash equivalents, trade receivables, loans, other receivables, borrowings, trade payables and other short-term payables is equivalent to the book value (net of provisions for estimated uncollectibility) of these items due to their short maturity.
- The fair value of loans, trade receivables, other receivables, borrowings, trade payables and other long-term payables, held-to-maturity investments that are not listed on the stock market and do not have a trading price announced by 3 securities companies is estimated by discounting cash flows at the interest rate applicable to debts with similar characteristics and remaining maturity.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

3. Credit risk

Credit risk is the risk that a party to a contract will not be able to perform its obligations resulting in financial loss to the Company.

The Company is exposed to credit risk from its operating activities (primarily trade receivables) and financing activities (bank deposits, loans and other financial instruments).

Accounts receivable

The Company minimizes credit risk by only dealing with financially sound entities, requiring letters of credit to be opened for entities that are trading for the first time or have no information on their financial capabilities, and having accounts receivable staff regularly monitor receivables to urge collection. On this basis, and the Company's receivables are related to many different customers, credit risk is not concentrated on a particular customer.

Depositechorow

Most of the bank deposits of The company is deposited in large, reputable banks in Vietnam. The company finds that the level of concentration of credit risk for bank deposits is low.

4. Riskliquidity risk

Liquidity risk is the risk The company had difficulty meeting its financial obligations due to lack of funds.

The Board of Directors has ultimate responsibility for liquidity risk management. The Company's liquidity risk arises primarily from the mismatch of maturities between its financial assets and financial liabilities.

The Company manages liquidity risk by maintaining an appropriate level of cash and cash equivalents and borrowings at levels deemed necessary by the Board. The leadership considers it sufficient to meet the operational needs of the The company aims to minimize the impact of cash flow fluctuations.

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

The maturity of financial liabilities based on undiscounted contractual payments is as follows:

	1 year or less	Over 1 year to 5 years	Over 5 years	Total
Ending Balance				
Loans and Debts	29,625,095,827	-	-	29,625,095,827
Payable to seller	1,124,723,591	-	-	1,124,723,591
Other payables	92,782,884,802	-	-	92,782,884,802
Total	123,532,704,220	-	-	123,532,704,220
Beginning Balance				
Loans and Debts	31,778,533,650	-	-	31,778,533,650
Payable to seller	6,073,280,479	-	-	6,073,280,479
Other payables	89,905,330,840	-	-	89,905,330,840
Total	127,757,144,969	-	-	127,757,144,969

The Company believes that the concentration of risk with respect to debt repayment is low. The Company is able to repay its debts when they fall due from cash flows from operations and proceeds from maturing financial assets.

5. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk includes three types: currency risk, interest rate risk and other price risk.

The sensitivity analyses presented below are based on a constant value of net debt, with the ratio of fixed-rate debt to floating-rate debt remaining constant.

Foreign exchange risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Interest rate risk of Company mainly related to money and loans.

The Company manages interest rate risk by analyzing market conditions to obtain the most favorable interest rates while remaining within its risk management limits.

Other price risks

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices other than changes in interest rates and foreign exchange rates.

6. Significant events occurring during and subsequent to the end of the accounting period

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. Currently, the Company is carrying out the necessary procedures to put the chain of clinic companies in all 63 provinces and cities across the country into operation, with the expectation of providing early, reliable diagnostic tests at the most cost-effective cost at the chain of testing centers. This issue was also approved at the 2024 Annual General Meeting of Shareholders.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Maternity and Pediatrics Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 8 billion to the company.

- Resolution of the Board of Directors No. 2502.01/2025/NQ-HĐQT dated February 25, 2025 on divestment of investment capital at Vietnam National Software Production Joint Stock Company.

7. Comparison information

Comparative figures on the Interim Balance Sheet are the figures on the Balance Sheet as of December 31, 2023 audited by TTP Auditing Company Limited. Comparative figures on the Interim Income Statement and Interim Cash Flow Statement are the figures on the Interim Income Statement and Interim Cash Flow Statement for the first 6 months of the fiscal year ended December 31, 2023 audited by TTP Auditing Company Limited.

Due to changes in interest payable according to the balance confirmation letter of Viet Capital Commercial Joint Stock Bank, some beginning-of-year indicators on the Interim Balance Sheet, Interim Business Performance Report and Interim Cash Flow Statement are adjusted specifically as follows:

AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements(next)

		Figures based on the audited financial statements of the previous year	Restated figures	Adjusted figures
Balance sheet	Code			
Short-term payable expenses	315	9,620,385,088	4,353,675,752	13,974,060,840
Undistributed profit after tax	421	251.248.913.639	(4,353,675,752)	246.895.237.887
Undistributed profit after tax accumulated to the end of previous period	421a	215.505.662.285	(2,723,695,863)	212,781,966,422
Undistributed profit this period	421b	35,743,251,354	(1,629,979,889)	34,113,271,465
Business performance report				
Financial costs	22	7,939,706,048	1,629,979,889	9,569,685,937
Including: interest expense	23	2,355,993,265	1,629,979,889	3,985,973,154
Total accounting profit before tax	50	4.010.252.255	(1,629,979,889)	2,380,272,366
Profit after corporate income tax	60	4.010.252.255	(1,629,979,889)	2,380,272,366
Cash flow statement				
Profit before tax	03	4.010.252.255	(1,629,979,889)	2,380,272,366
Interest expense	06	2,355,993,265	1,629,979,889	3,985,973,154

Prepared on 23 May, 2025

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Director



Dang Nhi Nuong